髓源性抑制细胞
免疫系统
CD14型
免疫疗法
免疫抑制
癌症
癌症研究
血管生成
人口
转移
癌症免疫疗法
医学
肿瘤微环境
抑制器
免疫学
内科学
环境卫生
出处
期刊:Life Sciences
[Elsevier]
日期:2021-07-01
卷期号:277: 119627-119627
被引量:41
标识
DOI:10.1016/j.lfs.2021.119627
摘要
Myeloid-derived suppressor cells (MDSCs) are heterogeneous and poorly mature cells of innate immunity that their population is increased substantially in cancer patients. MDSCs represent three subsets including CD14+ monocytic (M), CD15+ granulocytic (G) and Lin− early precursor (e) cells. MDSCs release a number of factors that direct several tumorigenic-related events including immune evasion, angiogenesis and metastasis. Assessment of MDSCs can provide valuable information from cancer immunity state, and it can be an indicator of tumor prognosis. The cells can be targeted in combination with current immunotherapeutic schedules, and the outcomes were promising. The focus of this review is to provide an overview of MDSCs, their involvement in tumor-related immunosuppression, and their impact on cancer immunotherapy. Then, strategies are proposed to boost the power of immune system against MDSCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI